A total of 17 studies met the inclusion criteria. 5 key findings →
Design: prospective cohort Participants: 17 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Research
31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
The presence of burst suppression, which was unexpectedly high in this medical intensive care unit population, was an independent predictor of increased risk of death at 6 months. 5 key findings →
Design: cohort study Participants: 125 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Changing staff practice in nursing homes is possible but complex. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Delirium increases risk of future cognitive decline and dementia, independent of illness severity and baseline cognition, with more episodes associated with worse cognitive outcomes. 5 key findings →
Participants: 205 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Although psychotropic drug use has been associated with increased risk of falls in long-term care settings; this association may be confounded by the high prevalence of dementia and depression and other fall risk factors. 4 key findings →
Design: cohort study Participants: 178 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Elevated preoperative and postoperative plasma levels of C-reactive protein were associated with delirium, suggesting that a preinflammatory state and heightened inflammatory response to surgery are potential pathophysiologic mechanisms of delirium. 4 key findings →
Design: case-control study Participants: 566 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Urinary tract infections, pressure areas, pneumonia and delirium are potentially preventable hospital-acquired complications. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
An increased incidence of mild cognitive impairment was observed in community-dwelling elderly adults who had nonpsychotic psychiatric symptoms at baseline. 3 key findings →
Design: cohort study Participants: 365 Evidence: moderate
Full summary, score breakdown and related studies → Original source
60/100
Neuropsychiatric symptoms are common features of MCI. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
In a longitudinal study of senile dementia and healthy aging, the occurrence of serious falls was examined in participants with senile dementia of the Alzheimer's type (SDAT) (n = 44) and in cognitively healthy elderly control participants (n = 56) over a 4-year period. 4 key findings →
Design: longitudinal study Participants: 44 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study provides longitudinal evidence for a decline in driving performance over time, primarily in early-stage DAT, and supports the need not only for driving assessments, but also for reevaluation of individuals with very mild and mild DAT. 3 key findings →
Design: longitudinal study Participants: 21 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Two out of five elderly patients in general hospitals suffer from a cognitive disturbance. 1 key finding →
Design: cross-sectional Participants: 1,469 Evidence: low
Full summary, score breakdown and related studies → Original source
The novel respiratory disease COVID-19 produces varying symptoms, with fever, cough, and shortness of breath being common. 3 key findings →
Participants: 16,749 Evidence: low
Full summary, score breakdown and related studies → Original source
Outcomes of interest were duration of delirium, health-related quality of life, delirium severity, cognitive function, mortality in the ICU, ICU length of stay, hospital length of stay and adverse events. 5 key findings →
Design: meta-analysis Participants: 491 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
PLWD also commonly experience social isolation (Shen et al., 2022), poorer physical function (Jehu et al., 2024a), worsened behavioral and psychological symptoms (Cerejeira et al., 2012), poorer quality of life (Cerejeira et al., 2012), and reduced access to healthcare (Mitchell et al., 2016) compared to older adults without dementia. 5 key findings →
Design: randomized controlled trial Participants: 21 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Anemia among older adults aged ≥ 60 years is a well-described risk factor that increases the risk of falls, cardiovascular diseases, and mortality. 4 key findings →
Design: longitudinal study Participants: 3,252 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Ultimately, 10,373 participants were included in the analysis. 5 key findings →
Design: longitudinal study Participants: 10,373 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
1,318 unique titles and abstracts were screened, of which 20 articles met inclusion criteria. 5 key findings →
Design: systematic review Participants: 12,132 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Unlike nigrostriatal dopaminergic denervation, cholinergic hypofunction is associated with fall status in Parkinson disease (PD). 5 key findings →
Design: cross-sectional Participants: 44 Evidence: low
Full summary, score breakdown and related studies → Original source
57/100
No definitive conclusions about the superiority of any of the tested interventions can be made. 3 key findings →
Participants: 259 Evidence: high
Full summary, score breakdown and related studies → Original source
Cognitive and mood disorders were common in elderly hip fracture patients and were associated with greater risk of poor outcomes, both independently and in combination. 4 key findings →
Design: prospective cohort Evidence: moderate
Full summary, score breakdown and related studies → Original source
In a community-dwelling population with generally mild AD, hospitalization is frequent, occurring in two-thirds of participants over a median follow-up time of 3 years. 3 key findings →
Design: prospective cohort Evidence: moderate
Full summary, score breakdown and related studies → Original source
While delirium is associated with cognitive decline and dementia, there is limited evidence to support causality for this relationship. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
These findings suggest that non-AD, but not AD dementia, is associated with increased falls in comparison with CHIs. 5 key findings →
Design: cross-sectional Participants: 529 Evidence: low
Full summary, score breakdown and related studies → Original source
Postvaccination meningoencephalitis occurred without clear relation to serum anti-Abeta42 antibody titers.
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events